AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: AZD2066

Study type: Interventional

Funder types: Industry

Identifiers

NCT00690404

D0475C00005

Details and patient eligibility

About

A open label two way crossover formulation and food effect study in healthy volunteers to assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an oral solution

Enrollment: 20 patients

Sex: All

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and laboratory assessments
• Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg

Exclusion criteria

• History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.
• History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.

Trial design

20 participants in 1 patient group

1

Experimental group

Treatment:

Drug: AZD2066